Filing Flows › Comparisons › RIGL vs EOLS
Rigel Pharmaceuticals vs Evolus: RIGL and EOLS compared
Rigel Pharmaceuticals is the larger company: $80.9M of revenue in its latest quarter (Q3 2026) against $78.0M for Evolus (Q3 2026). Rigel Pharmaceuticals is growing faster (+16% against +13% a year earlier). Rigel Pharmaceuticals is more profitable, with an operating margin of 21.1% against -10.8%.
Where the money goes: RIGL and EOLS
Rigel Pharmaceuticals (RIGL) · Q3 2026
Rigel Pharmaceuticals, Q3 2026: revenue $80.9M (+16% year over year), operating margin 21.1%, net earnings $13.2M, operating cash flow $34.6M. The chart follows the revenue to costs, profit and cash.
Evolus (EOLS) · Q3 2026
Evolus, Q3 2026: revenue $78.0M (+13% year over year), operating margin -10.8%, net loss $12.5M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
| Rigel Pharmaceuticals (RIGL) | Evolus (EOLS) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $80.9M | $78.0M |
| Revenue growth, Y/Y | +16% | +13% |
| Operating margin | 21.1% | -10.8% |
| Net earnings | $13.2M | −$12.5M |
| Net margin | 16.3% | -16.1% |
| Operating cash flow | $34.6M | −$1.9M |
Where the revenue comes from
Rigel Pharmaceuticals
- Product sales, net: $72.3M (89%)
- Contract revenues from collaborations and other: $8.6M (11%)
Evolus
- Product revenue, net: $77.2M (99%)
- Service revenue: $741K (1%)
Questions
Which is bigger, Rigel Pharmaceuticals or Evolus?
Rigel Pharmaceuticals is the larger company: $80.9M of revenue in its latest quarter (Q3 2026) against $78.0M for Evolus (Q3 2026).
Is Rigel Pharmaceuticals or Evolus growing faster?
Rigel Pharmaceuticals is growing faster (+16% against +13% a year earlier).
Which is more profitable, Rigel Pharmaceuticals or Evolus?
Rigel Pharmaceuticals is more profitable, with an operating margin of 21.1% against -10.8%.
More: Rigel Pharmaceuticals earnings · how Rigel Pharmaceuticals makes money · Evolus earnings · how Evolus makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.